TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $11.00 target price on the stock. Needham & Company LLC’s price target indicates a potential upside of 103.70% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, TScan Therapeutics presently has an average rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Price Performance

NASDAQ:TCRX traded down $0.30 during trading hours on Tuesday, reaching $5.40. 99,615 shares of the company were exchanged, compared to its average volume of 246,889. The business has a 50 day moving average of $5.35 and a 200 day moving average of $6.54. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.77 and a quick ratio of 7.77. The company has a market capitalization of $286.06 million, a P/E ratio of -5.14 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $1.55 million. Research analysts forecast that TScan Therapeutics will post -1.17 EPS for the current year.

Insider Activity at TScan Therapeutics

In related news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was acquired at an average price of $5.53 per share, with a total value of $27,650.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $221,200. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Barbara Klencke bought 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $5.53 per share, with a total value of $27,650.00. Following the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $221,200. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now directly owns 4,716 shares in the company, valued at $27,258.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have purchased 15,000 shares of company stock valued at $82,550. 2.76% of the stock is owned by insiders.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics during the second quarter worth $70,000. The Manufacturers Life Insurance Company bought a new position in TScan Therapeutics during the 2nd quarter worth $90,000. SG Americas Securities LLC acquired a new position in TScan Therapeutics during the 3rd quarter worth about $78,000. American Century Companies Inc. grew its position in shares of TScan Therapeutics by 48.9% in the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock valued at $278,000 after buying an additional 15,596 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of TScan Therapeutics by 1.1% in the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after buying an additional 20,000 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.